Gregory Blair, MD
Hematology/Oncology · Carmichael
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 43 years
- St. Louis College of Physicians and Surgeons, 1983
Offices
1 location · Sierra Hematology and Oncology Medical Centers · 15 clinicians in this group
Hospitals listed: Sutter Medical Center, Sacramento. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Blair’s office at (916) 962-1544 to ask if they take your plan before you enroll.
California Medical Board record
Licence G65481 · Current
Licensed to practise in California · since 1989 · expires 2027-02-28 · Saint Louis University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$544,298
Medicare paid this office $544,298 for 74 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 63 | $10,494 | $71 |
| Return visit (30+ min) | 31 | $7,040 | $105 |
| Insertion of needle into vein for collection of blood sample | 38 | $1,361 | $8 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 33 | $1,073 | $8 |
Who their Medicare patients are
74 Original Medicare patients in 2024. Average age 73 · Women 66% · Also on Medicaid 51% · Health risk score 1.60. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: Cancer 72% · High blood pressure 65% · Diabetes 27% · COPD 22% · Chronic kidney disease 20%.
The office billed $1,725,245, Medicare allowed $682,128 and paid $544,298; for 25,591 services of 60 kinds; $500,519 of it was for drugs given in the office and $43,779 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 74 | 25,591 | 73 | 1.60 | $1,725,245 | $544,298 |
| 2023 | 80 | 29,407 | 72 | 1.53 | $1,806,912 | $600,777 |
| 2022 | 66 | 20,058 | 71 | 1.43 | $1,061,713 | $331,424 |
| 2021 | 29 | 8,802 | 73 | 1.40 | $335,536 | $111,623 |
| 2020 | 22 | 2,428 | 73 | 1.86 | $156,986 | $63,978 |
| 2019 | 481 | 81,527 | 72 | 1.84 | $2,401,198 | $1,012,103 |
| 2018 | 658 | 130,177 | 71 | 1.69 | $4,695,827 | $2,125,720 |
| 2017 | 409 | 78,786 | 71 | 1.61 | $3,030,629 | $1,336,491 |
| 2016 | 428 | 68,660 | 72 | 1.53 | $2,756,946 | $913,439 |
| 2015 | 509 | 70,471 | 72 | 1.52 | $2,436,821 | $917,309 |
| 2014 | 598 | 89,082 | 72 | 1.46 | $2,788,198 | $1,066,879 |
| 2013 | 556 | 75,801 | 71 | 1.54 | $2,777,912 | $1,143,148 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Administration of chemotherapy into vein, 1 hour or less | 11 | $10,999 | $115 |
| Short return visit (20+ min) | 66 | $9,863 | $69 |
| Return visit (30+ min) | 29 | $6,211 | $104 |
| New patient visit (45+ min) | 16 | $2,257 | $141 |
| Insertion of needle into vein for collection of blood sample | 48 | $1,007 | $7 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 41 | $928 | $8 |
2022: 5 services
| Short return visit (20+ min) | 50 | $7,616 | $73 |
| Return visit (30+ min) | 27 | $4,019 | $98 |
| New patient visit (45+ min) | 12 | $1,688 | $141 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 35 | $833 | $8 |
| Insertion of needle into vein for collection of blood sample | 35 | $289 | $3 |
2021: 1 service
| Short return visit (20+ min) | 18 | $3,403 | $71 |
2019: 29 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 90 | $48,138 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 40 | $34,243 | $120 |
| Short return visit (20+ min) | 373 | $26,596 | $47 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 27 | $20,453 | None |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 21 | $16,352 | $9 |
| Return visit (30+ min) | 77 | $9,946 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $9,823 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 37 | $8,795 | $58 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 204 | $6,218 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 13 | $4,986 | $59 |
| New patient visit (45+ min) | 42 | $4,915 | $117 |
| Injection of drug or substance under skin or into muscle | 60 | $3,406 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 29 | $3,108 | $18 |
| Insertion of needle into vein for collection of blood sample | 267 | $2,934 | $3 |
| Injection of additional new drug or substance into vein | 25 | $2,916 | $14 |
| Administration of additional new drug or substance into vein using push technique | 11 | $2,756 | $51 |
| Administration of chemotherapy into vein, each additional hour | 20 | $2,347 | $25 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $1,986 | $33 |
| Drawing of blood for a medical problem | 11 | $1,635 | $71 |
| Blood test, comprehensive group of blood chemicals | 40 | $1,209 | $12 |
| Injection, zoledronic acid, 1 mg | 12 | $919 | None |
| Infusion into a vein for hydration, each additional hour | 22 | $848 | $11 |
| Irrigation of implanted venous access drug delivery device | 19 | $708 | $17 |
| Injection, ondansetron hydrochloride, per 1 mg | 34 | $438 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $367 | $18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 34 | $259 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $53 | None |
| Infusion, normal saline solution, 250 cc | 16 | $38 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 14 | $36 | None |
2018: 42 services
| Injection, rituximab, 100 mg | 11 | $261,030 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 139 | $142,218 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $71,526 | $121 |
| Short return visit (20+ min) | 510 | $56,676 | $56 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 40 | $46,976 | None |
| Return visit (30+ min) | 174 | $27,994 | $83 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 56 | $15,941 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 62 | $14,544 | $61 |
| New patient visit (45+ min) | 116 | $14,247 | $123 |
| Injection, ferric carboxymaltose, 1 mg | 11 | $11,855 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 251 | $10,255 | $9 |
| Injection of additional new drug or substance into vein | 50 | $8,267 | $15 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $7,830 | $58 |
| Injection of drug or substance under skin or into muscle | 78 | $6,709 | $17 |
| Insertion of needle into vein for collection of blood sample | 389 | $5,639 | $3 |
| Administration of chemotherapy into vein, each additional hour | 36 | $5,323 | $26 |
| Administration of chemotherapy into vein using push technique | 14 | $4,442 | $93 |
| Injection, zoledronic acid, 1 mg | 32 | $4,022 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 35 | $3,484 | $32 |
| Blood test, comprehensive group of blood chemicals | 83 | $3,054 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 36 | $2,893 | $18 |
| Drawing of blood for a medical problem | 12 | $2,806 | $83 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,577 | $26 |
| Irrigation of implanted venous access drug delivery device | 39 | $2,313 | $21 |
| Administration of additional new drug or substance into vein using push technique | 12 | $2,304 | $50 |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $1,580 | $37 |
| Infusion into a vein for hydration, each additional hour | 35 | $1,573 | $11 |
| Injection, paclitaxel, 1 mg | 15 | $1,567 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,245 | $59 |
| Injection, carboplatin, 50 mg | 12 | $1,020 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $882 | $18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 55 | $504 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $474 | $18 |
| Injection, ondansetron hydrochloride, per 1 mg | 52 | $413 | None |
| Injection, fluorouracil, 500 mg | 11 | $358 | None |
| Injection, granisetron hydrochloride, 100 mcg | 18 | $205 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $149 | None |
| Infusion, normal saline solution , 1000 cc | 18 | $118 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $85 | None |
| Unclassified drugs | 17 | $79 | None |
| Infusion, normal saline solution, 250 cc | 34 | $77 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 18 | $33 | None |
2017: 30 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 110 | $153,451 | $151 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $44,352 | None |
| Administration of chemotherapy into vein, 1 hour or less | 36 | $41,497 | $110 |
| Return visit (30+ min) | 179 | $31,835 | $76 |
| Short return visit (20+ min) | 298 | $29,158 | $53 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 209 | $11,014 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 34 | $9,568 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $9,348 | $55 |
| Injection of additional new drug or substance into vein | 36 | $8,003 | $18 |
| Administration of chemotherapy into vein using push technique | 11 | $6,238 | $89 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $5,682 | $53 |
| Administration of chemotherapy into vein, each additional hour | 26 | $4,811 | $23 |
| New patient visit (45+ min) | 35 | $4,245 | $121 |
| Blood test, comprehensive group of blood chemicals | 79 | $4,033 | $14 |
| Insertion of needle into vein for collection of blood sample | 234 | $3,844 | $3 |
| Injection of drug or substance under skin or into muscle | 30 | $3,486 | $20 |
| Infusion into a vein for hydration, each additional hour | 18 | $1,697 | $12 |
| Injection, zoledronic acid, 1 mg | 12 | $1,650 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,351 | $56 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 33 | $1,304 | None |
| Irrigation of implanted venous access drug delivery device | 19 | $1,235 | $19 |
| Injection, carboplatin, 50 mg | 11 | $1,171 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $1,098 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 19 | $910 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $320 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 28 | $318 | None |
| Infusion, normal saline solution, 250 cc | 35 | $160 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | $72 | None |
| Infusion, normal saline solution , 1000 cc | 16 | $56 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $55 | None |
2016: 35 services
| Return visit (30+ min) | 284 | $47,518 | $78 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $41,188 | None |
| Administration of chemotherapy into vein, 1 hour or less | 33 | $38,113 | $110 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 49 | $19,844 | $153 |
| Short return visit (20+ min) | 211 | $15,690 | $50 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 42 | $13,614 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 29 | $12,466 | $25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 179 | $9,332 | $10 |
| Administration of prolonged chemotherapy into vein | 11 | $9,077 | $115 |
| Injection of additional new drug or substance into vein | 34 | $8,695 | $18 |
| Administration of chemotherapy into vein using push technique | 12 | $8,061 | $89 |
| New patient visit (45+ min) | 41 | $5,131 | $125 |
| Injection, zoledronic acid, 1 mg | 22 | $4,964 | None |
| Administration of chemotherapy into vein, each additional hour | 26 | $4,661 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $4,339 | $51 |
| Blood test, comprehensive group of blood chemicals | 84 | $3,976 | $14 |
| Insertion of needle into vein for collection of blood sample | 209 | $3,660 | $3 |
| Injection of drug or substance under skin or into muscle | 30 | $3,055 | $20 |
| Irrigation of implanted venous access drug delivery device | 32 | $2,172 | $18 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 39 | $2,055 | None |
| Long return visit (40+ min) | 17 | $1,860 | $109 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $1,786 | $15 |
| Infusion into a vein for hydration, each additional hour | 16 | $1,719 | $12 |
| Injection, iron dextran, 50 mg | 11 | $1,672 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 15 | $1,538 | $17 |
| Injection of drug or substance into vein | 12 | $1,292 | $43 |
| Injection, fluorouracil, 500 mg | 11 | $961 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $624 | $31 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $408 | $14 |
| Injection, ondansetron hydrochloride, per 1 mg | 25 | $391 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 29 | $345 | None |
| Infusion, normal saline solution, 250 cc | 38 | $118 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | $76 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $63 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 16 | $46 | None |
2015: 23 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $66,490 | None |
| Return visit (30+ min) | 238 | $45,060 | $82 |
| Administration of chemotherapy into vein, 1 hour or less | 27 | $29,981 | $114 |
| Short return visit (20+ min) | 328 | $27,730 | $52 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $18,434 | $58 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 244 | $13,592 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 28 | $10,262 | $25 |
| Injection of additional new drug or substance into vein | 29 | $7,791 | $19 |
| Injection, zoledronic acid, 1 mg | 21 | $7,548 | None |
| New patient visit (45+ min) | 58 | $7,510 | $129 |
| Blood test, comprehensive group of blood chemicals | 148 | $5,055 | $14 |
| Injection of drug or substance under skin or into muscle | 41 | $5,010 | $21 |
| Insertion of needle into vein for collection of blood sample | 272 | $4,257 | $3 |
| Injection, iron dextran, 50 mg | 17 | $3,964 | None |
| Irrigation of implanted venous access drug delivery device | 32 | $3,000 | $20 |
| Administration of chemotherapy into vein, each additional hour | 20 | $2,933 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,467 | $59 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 34 | $2,058 | None |
| Infusion into a vein for hydration, each additional hour | 16 | $1,922 | $13 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,109 | $32 |
| Injection, dexamethasone sodium phosphate, 1 mg | 25 | $287 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 23 | $215 | None |
| Infusion, normal saline solution, 250 cc | 40 | $93 | None |
2014: 35 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $45,498 | None |
| Return visit (30+ min) | 251 | $43,966 | $81 |
| Short return visit (20+ min) | 405 | $38,886 | $54 |
| Administration of chemotherapy into vein, 1 hour or less | 46 | $34,073 | $111 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 61 | $20,995 | $57 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 319 | $16,737 | $10 |
| Administration of chemotherapy into vein using push technique | 15 | $14,179 | $91 |
| Injection, zoledronic acid, 1 mg | 27 | $13,256 | None |
| Injection of additional new drug or substance into vein | 54 | $12,151 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 49 | $9,619 | $25 |
| New patient visit (45+ min) | 70 | $8,953 | $128 |
| Blood test, comprehensive group of blood chemicals | 179 | $6,371 | $14 |
| Insertion of needle into vein for collection of blood sample | 347 | $5,163 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $4,397 | $26 |
| Injection of drug or substance under skin or into muscle | 53 | $4,369 | $20 |
| Injection, iron dextran, 50 mg | 23 | $3,601 | None |
| Drawing of blood for a medical problem | 15 | $3,578 | $69 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $3,479 | $50 |
| Administration of additional new drug or substance into vein using push technique | 11 | $3,336 | $51 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 54 | $3,312 | None |
| Administration of chemotherapy into vein, each additional hour | 20 | $2,773 | $23 |
| Infusion into a vein for hydration, each additional hour | 27 | $2,513 | $13 |
| Irrigation of implanted venous access drug delivery device | 27 | $2,102 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,035 | $58 |
| New patient visit (60+ min) | 12 | $1,953 | $163 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $1,737 | $32 |
| Injection, carboplatin, 50 mg | 13 | $741 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $532 | $15 |
| Injection, ondansetron hydrochloride, per 1 mg | 44 | $416 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 47 | $339 | None |
| Infusion, normal saline solution, 250 cc | 38 | $84 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $34 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $30 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $26 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $21 | None |
2013: 31 services
| Injection, fulvestrant, 25 mg | 11 | $108,879 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 18 | $52,530 | None |
| Short return visit (20+ min) | 409 | $41,181 | $54 |
| Administration of chemotherapy into vein, 1 hour or less | 38 | $39,755 | $121 |
| Return visit (30+ min) | 188 | $35,423 | $85 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 55 | $23,759 | $63 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 317 | $17,722 | $10 |
| Zoldedronic acid 1mg | 11 | $13,438 | $136 |
| Injection of additional new drug or substance into vein | 41 | $10,170 | $19 |
| New patient visit (45+ min) | 64 | $8,288 | $129 |
| Injection of drug or substance under skin or into muscle | 58 | $8,074 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 34 | $7,651 | $27 |
| Blood test, comprehensive group of blood chemicals | 169 | $5,670 | $14 |
| Insertion of needle into vein for collection of blood sample | 331 | $5,267 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $5,132 | $27 |
| Injection, iron dextran, 50 mg | 25 | $4,006 | None |
| Administration of chemotherapy into vein, each additional hour | 24 | $3,624 | $26 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 44 | $3,271 | None |
| Drawing of blood for a medical problem | 14 | $2,908 | $66 |
| Administration of additional new drug or substance into vein using push technique | 12 | $2,526 | $52 |
| Infusion into a vein for hydration, each additional hour | 23 | $2,380 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,199 | $56 |
| Irrigation of implanted venous access drug delivery device | 26 | $1,865 | $20 |
| New patient visit (60+ min) | 11 | $1,808 | $164 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $950 | $31 |
| Injection, ondansetron hydrochloride, per 1 mg | 28 | $400 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $282 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 34 | $230 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $130 | None |
| Infusion, normal saline solution, 250 cc | 23 | $52 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $26 | None |
Medicaid work
$2,554 in 2024
Medicaid paid $2,554 for 1,110 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 195 | $1,601 |
| OFF/OP EST MAY X REQ PHY/QHP | 267 | $266 |
| Return visit (30+ min) | 39 | $259 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 132 | $246 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 55 | $132 |
| Injection, ondansetron hydrochloride, per 1 mg | 48 | $27 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 181 | $16 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 193 | $8 |
| 2024 | 1,110 | 8 | 33 | $2,554 |
| 2023 | 2,624 | 13 | 29 | $103,686 |
| 2022 | 2,385 | 11 | 27 | $29,738 |
| 2021 | 79 | 4 | 14 | $1,286 |
| 2019 | 7,193 | 25 | 167 | $21,424 |
| 2018 | 9,650 | 25 | 125 | $138,615 |
See the largest Medicaid services in earlier years
2023
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 346 | $46,805 |
| Injection, dexamethasone sodium phosphate, 1 mg | 47 | $18,052 |
| OFF/OP EST MAY X REQ PHY/QHP | 461 | $11,318 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 204 | $9,494 |
| Short return visit (20+ min) | 271 | $8,020 |
| Injection, ondansetron hydrochloride, per 1 mg | 229 | $4,954 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 386 | $2,381 |
| Return visit (30+ min) | 72 | $2,353 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 63 | $149 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure) | 108 | $125 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 25 | $19 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 386 | $16 |
2022
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 356 | $13,097 |
| OFF/OP EST MAY X REQ PHY/QHP | 352 | $4,746 |
| Injection, dexamethasone sodium phosphate, 1 mg | 175 | $3,759 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure) | 92 | $2,522 |
| Return visit (30+ min) | 52 | $2,360 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 232 | $1,860 |
| Short return visit (20+ min) | 248 | $711 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 309 | $345 |
| Injection, ondansetron hydrochloride, per 1 mg | 232 | $314 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 290 | $20 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 47 | $3 |
2021
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 22 | $628 |
| OFF/OP EST MAY X REQ PHY/QHP | 23 | $588 |
| Short return visit (20+ min) | 14 | $66 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 20 | $5 |
2019
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 137 | $7,579 |
| Short return visit (20+ min) | 765 | $2,570 |
| New patient visit (45+ min) | 162 | $2,336 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 442 | $1,366 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 238 | $1,111 |
| Return visit (30+ min) | 187 | $1,060 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 515 | $960 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 629 | $679 |
| Injection, ondansetron hydrochloride, per 1 mg | 369 | $541 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 819 | $391 |
| Injection, dexamethasone sodium phosphate, 1 mg | 355 | $371 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 191 | $310 |
2018
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 543 | $20,293 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 394 | $19,216 |
| Short return visit (20+ min) | 1,074 | $18,118 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 757 | $17,756 |
| Return visit (30+ min) | 277 | $14,813 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 965 | $8,375 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 789 | $7,439 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 85 | $6,386 |
| OFF/OP EST MAY X REQ PHY/QHP | 877 | $4,291 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 133 | $4,164 |
| New patient visit (45+ min) | 227 | $3,250 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 354 | $2,947 |
Drugs they prescribed that Part D paid
$1,264,655
Pharmacies billed $1,264,655 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (37 of 581) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%.
485 generic and 96 brand-name prescriptions · $1,264,655 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 19 | $296,335 | $15,597 |
| Lynparza | 11 | $184,820 | $16,802 |
| Lenalidomide | 14 | $181,590 | $12,971 |
| Abiraterone Acetate | 16 | $25,600 | $1,600 |
| Eliquis | 15 | $11,038 | $736 |
See all 16 drugs
| Xtandi | 19 | $296,335 | $15,597 |
| Lynparza | 11 | $184,820 | $16,802 |
| Lenalidomide | 14 | $181,590 | $12,971 |
| Abiraterone Acetate | 16 | $25,600 | $1,600 |
| Eliquis | 15 | $11,038 | $736 |
| Aprepitant | 20 | $9,161 | $458 |
| Ondansetron | 55 | $5,144 | $94 |
| Exemestane | 20 | $3,439 | $172 |
| Anastrozole | 78 | $1,641 | $21 |
| Prochlorperazine Maleate | 35 | $456 | $13 |
| Hydrocodone-Acetaminophen | 23 | $439 | $19 |
| Ondansetron Odt | 19 | $435 | $23 |
| Lansoprazole | 13 | $390 | $30 |
| Dexamethasone | 19 | $169 | $9 |
| Prednisone | 36 | $149 | $4 |
| Pantoprazole | 14 | $103 | $7 |
Year by year
| 2024 | 581 | 79 | 6% (37) | 17% | $1,264,655 |
| 2023 | 451 | 82 | 11% (49) | 15% | $1,092,728 |
| 2022 | 319 | 74 | 7% (22) | 24% | $1,223,586 |
| 2021 | 182 | 37 | 12% (22) | 10% | $59,886 |
| 2020 | 78 | 38 | None | None | $56,581 |
| 2019 | 1,453 | 289 | 11% (156) | 19% | $2,010,336 |
| 2018 | 2,381 | 356 | 14% (339) | None | $2,815,406 |
| 2017 | 2,186 | 288 | 17% (372) | 15% | $2,167,693 |
| 2016 | 2,311 | 301 | 16% (371) | 16% | $1,872,935 |
| 2015 | 2,058 | 279 | 14% (291) | None | $1,403,317 |
| 2014 | 1,796 | 249 | 12% (223) | None | $758,126 |
| 2013 | 1,673 | 225 | 12% (197) | None | $702,185 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Lenvima | 12 | $341,241 | $28,437 |
| Xtandi | 20 | $310,245 | $15,512 |
| Everolimus | 12 | $70,863 | $5,905 |
| Exemestane | 18 | $3,491 | $194 |
| Anastrozole | 72 | $3,453 | $48 |
| Letrozole | 13 | $1,739 | $134 |
| Hydrocodone-Acetaminophen | 32 | $1,205 | $38 |
| Ondansetron | 33 | $545 | $17 |
| Ondansetron Odt | 18 | $415 | $23 |
| Prochlorperazine Maleate | 25 | $278 | $11 |
| Dexamethasone | 28 | $220 | $8 |
| Lansoprazole | 14 | $218 | $16 |
| Levothyroxine | 16 | $199 | $12 |
2022: 8 drugs
| Ibrance | 35 | $520,175 | $14,862 |
| Lenvima | 16 | $497,406 | $31,088 |
| Anastrozole | 67 | $2,231 | $33 |
| Letrozole | 15 | $747 | $50 |
| Ondansetron Odt | 16 | $658 | $41 |
| Hydrocodone-Acetaminophen | 17 | $301 | $18 |
| Dexamethasone | 16 | $245 | $15 |
| Prednisone | 11 | $46 | $4 |
2021: 6 drugs
| Anastrozole | 25 | $1,098 | $44 |
| Ondansetron Odt | 17 | $268 | $16 |
| Hydrocodone-Acetaminophen | 12 | $259 | $22 |
| Dexamethasone | 20 | $153 | $8 |
| Prednisone | 12 | $69 | $6 |
| Lorazepam | 12 | $39 | $3 |
2020: 1 drug
| Anastrozole | 17 | $440 | $26 |
2019: 26 drugs
| Revlimid | 26 | $416,026 | $16,001 |
| Ibrance | 25 | $305,496 | $12,220 |
| Jakafi | 16 | $214,900 | $13,431 |
| Promacta | 17 | $150,785 | $8,870 |
| Lupron Depot | 15 | $53,510 | $3,567 |
| Faslodex | 26 | $52,674 | $2,026 |
| Exemestane | 134 | $45,325 | $338 |
| Trelstar | 32 | $31,889 | $997 |
| Anastrozole | 371 | $8,412 | $23 |
| Aprepitant | 13 | $7,184 | $553 |
| Letrozole | 149 | $3,429 | $23 |
| Hydrocodone-Acetaminophen | 69 | $2,336 | $34 |
| Raloxifene | 15 | $2,210 | $147 |
| Gabapentin | 38 | $1,391 | $37 |
| Tamoxifen Citrate | 26 | $896 | $34 |
| Oxycodone | 22 | $810 | $37 |
| Morphine Sulfate Er | 13 | $792 | $61 |
| Oxycodone-Acetaminophen | 24 | $774 | $32 |
| Dexamethasone | 43 | $404 | $9 |
| Hydroxyurea | 11 | $388 | $35 |
| Ondansetron Odt | 32 | $244 | $8 |
| Ondansetron | 24 | $159 | $7 |
| Prochlorperazine Maleate | 20 | $153 | $8 |
| Acyclovir | 30 | $129 | $4 |
| Levothyroxine | 11 | $88 | $8 |
| Lorazepam | 18 | $50 | $3 |
2018: 42 drugs
| Ibrance | 46 | $541,741 | $11,777 |
| Revlimid | 36 | $541,654 | $15,046 |
| Zydelig | 25 | $260,096 | $10,404 |
| Jakafi | 15 | $198,483 | $13,232 |
| Promacta | 17 | $121,065 | $7,121 |
| Neulasta | 12 | $114,512 | $9,543 |
| Faslodex | 35 | $70,238 | $2,007 |
| Exemestane | 150 | $56,735 | $378 |
| Lupron Depot | 16 | $47,391 | $2,962 |
| Procrit | 11 | $45,893 | $4,172 |
| Trelstar | 38 | $32,856 | $865 |
| Aprepitant | 45 | $27,087 | $602 |
| Oxycontin | 12 | $13,998 | $1,167 |
| Anastrozole | 508 | $7,320 | $14 |
| Eliquis | 18 | $6,696 | $372 |
| Dronabinol | 13 | $6,438 | $495 |
| Raloxifene | 33 | $4,195 | $127 |
| Hydrocodone-Acetaminophen | 126 | $3,814 | $30 |
| Letrozole | 199 | $3,533 | $18 |
| Morphine Sulfate Er | 49 | $3,393 | $69 |
| Tamoxifen Citrate | 40 | $1,897 | $47 |
| Oxycodone-Acetaminophen | 48 | $1,711 | $36 |
| Oxycodone | 31 | $1,272 | $41 |
| Fentanyl | 17 | $1,135 | $67 |
| Gabapentin | 42 | $1,102 | $26 |
| Hydroxyurea | 40 | $970 | $24 |
| Megestrol Acetate | 27 | $965 | $36 |
| Duloxetine | 18 | $927 | $51 |
| Nystatin | 30 | $725 | $24 |
| Ondansetron Odt | 59 | $643 | $11 |
| Potassium Chloride | 22 | $641 | $29 |
| Dexamethasone | 64 | $459 | $7 |
| Lorcet Hd | 14 | $403 | $29 |
| Diphenoxylate-Atropine | 18 | $323 | $18 |
| Ondansetron | 34 | $278 | $8 |
| Prednisone | 37 | $208 | $6 |
| Acyclovir | 41 | $200 | $5 |
| Prochlorperazine Maleate | 32 | $177 | $6 |
| Lorazepam | 46 | $128 | $3 |
| Tramadol | 33 | $109 | $3 |
| Omeprazole | 17 | $76 | $4 |
| Allopurinol | 11 | $71 | $6 |
2017: 40 drugs
| Revlimid | 44 | $554,414 | $12,600 |
| Jakafi | 18 | $198,958 | $11,053 |
| Zydelig | 18 | $149,713 | $8,317 |
| Imatinib Mesylate | 17 | $143,593 | $8,447 |
| Gilotrif | 11 | $85,709 | $7,792 |
| Procrit | 20 | $78,582 | $3,929 |
| Exemestane | 111 | $43,592 | $393 |
| Lupron Depot | 13 | $34,810 | $2,678 |
| Fondaparinux | 12 | $30,344 | $2,529 |
| Aprepitant | 33 | $26,360 | $799 |
| Trelstar | 29 | $23,577 | $813 |
| Dronabinol | 15 | $7,585 | $506 |
| Anastrozole | 492 | $6,100 | $12 |
| Raloxifene | 57 | $6,023 | $106 |
| Eliquis | 11 | $4,178 | $380 |
| Morphine Sulfate Er | 41 | $3,896 | $95 |
| Hydrocodone-Acetaminophen | 150 | $3,489 | $23 |
| Fentanyl | 32 | $3,143 | $98 |
| Nexium | 12 | $3,074 | $256 |
| Letrozole | 191 | $2,577 | $13 |
| Oxycodone | 46 | $2,018 | $44 |
| Promethazine | 19 | $2,001 | $105 |
| Tamoxifen Citrate | 59 | $1,876 | $32 |
| Oxycodone-Acetaminophen | 37 | $1,311 | $35 |
| Duloxetine | 21 | $1,299 | $62 |
| Potassium Chloride | 12 | $747 | $62 |
| Lorcet Hd | 23 | $740 | $32 |
| Megestrol Acetate | 26 | $704 | $27 |
| Hydroxyurea | 43 | $697 | $16 |
| Gabapentin | 51 | $599 | $12 |
| Dexamethasone | 42 | $351 | $8 |
| Diphenoxylate-Atropine | 14 | $329 | $24 |
| Lorazepam | 76 | $259 | $3 |
| Ondansetron | 37 | $204 | $6 |
| Prednisone | 28 | $194 | $7 |
| Ondansetron Odt | 14 | $163 | $12 |
| Nystatin | 14 | $157 | $11 |
| Allopurinol | 13 | $122 | $9 |
| Prochlorperazine Maleate | 13 | $85 | $7 |
| Tramadol | 25 | $48 | $2 |
2016: 37 drugs
| Revlimid | 32 | $355,332 | $11,104 |
| Ibrance | 24 | $244,567 | $10,190 |
| Pomalyst | 20 | $209,831 | $10,492 |
| Xtandi | 15 | $135,923 | $9,062 |
| Tarceva | 16 | $109,985 | $6,874 |
| Gilotrif | 13 | $94,469 | $7,267 |
| Procrit | 21 | $78,733 | $3,749 |
| Lupron Depot | 17 | $60,321 | $3,548 |
| Exemestane | 114 | $35,219 | $309 |
| Emend | 32 | $27,223 | $851 |
| Trelstar | 23 | $18,545 | $806 |
| Morphine Sulfate Er | 36 | $9,959 | $277 |
| Anastrozole | 568 | $6,809 | $12 |
| Hydrocodone-Acetaminophen | 154 | $6,532 | $42 |
| Dronabinol | 11 | $6,255 | $569 |
| Raloxifene | 49 | $5,877 | $120 |
| Oxycodone-Acetaminophen | 48 | $5,067 | $106 |
| Letrozole | 204 | $3,642 | $18 |
| Fentanyl | 38 | $3,595 | $95 |
| Nexium | 11 | $2,856 | $260 |
| Megestrol Acetate | 31 | $1,886 | $61 |
| Hydromorphone | 41 | $1,870 | $46 |
| Hydroxyurea | 48 | $1,358 | $28 |
| Oxycodone | 25 | $1,296 | $52 |
| Tamoxifen Citrate | 42 | $1,006 | $24 |
| Duloxetine | 22 | $916 | $42 |
| Ondansetron | 89 | $791 | $9 |
| Lorazepam | 123 | $720 | $6 |
| Doxycycline Hyclate | 12 | $475 | $40 |
| Nystatin | 13 | $293 | $23 |
| Dexamethasone | 37 | $278 | $8 |
| Gabapentin | 24 | $228 | $10 |
| Ibuprofen | 17 | $216 | $13 |
| Prochlorperazine Maleate | 25 | $172 | $7 |
| Pantoprazole | 19 | $137 | $7 |
| Allopurinol | 11 | $107 | $10 |
| Alprazolam | 13 | $54 | $4 |
2015: 36 drugs
| Revlimid | 23 | $232,605 | $10,113 |
| Gleevec | 22 | $211,612 | $9,619 |
| Ibrance | 15 | $157,058 | $10,471 |
| Tarceva | 22 | $139,591 | $6,345 |
| Xtandi | 15 | $131,415 | $8,761 |
| Pomalyst | 13 | $101,973 | $7,844 |
| Procrit | 29 | $101,034 | $3,484 |
| Exemestane | 122 | $39,993 | $328 |
| Lupron Depot | 13 | $37,720 | $2,902 |
| Trelstar | 17 | $13,925 | $819 |
| Emend | 14 | $13,885 | $992 |
| Raloxifene | 44 | $8,441 | $192 |
| Morphine Sulfate Er | 25 | $7,953 | $318 |
| Anastrozole | 587 | $7,941 | $14 |
| Hydrocodone-Acetaminophen | 142 | $5,556 | $39 |
| Dronabinol | 12 | $5,300 | $442 |
| Spiriva | 12 | $3,755 | $313 |
| Oxycodone-Acetaminophen | 39 | $3,445 | $88 |
| Fentanyl | 28 | $3,058 | $109 |
| Letrozole | 229 | $2,430 | $11 |
| Megestrol Acetate | 19 | $2,258 | $119 |
| Hydromorphone | 28 | $1,708 | $61 |
| Hydroxyurea | 42 | $1,348 | $32 |
| Oxycodone | 17 | $1,062 | $62 |
| Tamoxifen Citrate | 29 | $898 | $31 |
| Ondansetron | 37 | $625 | $17 |
| Diphenoxylate-Atropine | 14 | $484 | $35 |
| Lorazepam | 97 | $338 | $3 |
| Gabapentin | 29 | $311 | $11 |
| Prochlorperazine Maleate | 28 | $250 | $9 |
| Dexamethasone | 31 | $116 | $4 |
| Ibuprofen | 13 | $113 | $9 |
| Warfarin | 14 | $96 | $7 |
| Prednisone | 12 | $81 | $7 |
| Zolpidem | 13 | $67 | $5 |
| Pantoprazole | 11 | $61 | $6 |
2014: 27 drugs
| Revlimid | 15 | $131,200 | $8,747 |
| Pomalyst | 11 | $81,809 | $7,437 |
| Procrit | 15 | $41,295 | $2,753 |
| Exemestane | 98 | $34,085 | $348 |
| Lupron Depot | 12 | $27,564 | $2,297 |
| Anastrozole | 543 | $14,225 | $26 |
| Trelstar | 13 | $10,803 | $831 |
| Dronabinol | 12 | $8,682 | $723 |
| Raloxifene | 24 | $5,557 | $232 |
| Hydrocodone-Acetaminophen | 129 | $4,673 | $36 |
| Morphine Sulfate Er | 13 | $4,249 | $327 |
| Evista | 13 | $3,687 | $284 |
| Oxycodone | 11 | $3,349 | $304 |
| Letrozole | 201 | $3,327 | $17 |
| Fentanyl | 16 | $2,327 | $145 |
| Hydroxyurea | 54 | $2,243 | $42 |
| Oxycodone-Acetaminophen | 19 | $1,791 | $94 |
| Hydromorphone | 21 | $1,646 | $78 |
| Tamoxifen Citrate | 59 | $1,125 | $19 |
| Gabapentin | 60 | $826 | $14 |
| Ondansetron | 41 | $510 | $12 |
| Lorazepam | 79 | $401 | $5 |
| Prochlorperazine Maleate | 33 | $331 | $10 |
| Megestrol Acetate | 18 | $278 | $15 |
| Zolpidem | 21 | $207 | $10 |
| Warfarin | 19 | $142 | $7 |
| Dexamethasone | 12 | $63 | $5 |
2013: 23 drugs
| Revlimid | 41 | $297,349 | $7,252 |
| Lupron Depot | 12 | $23,333 | $1,944 |
| Exemestane | 65 | $20,688 | $318 |
| Evista | 64 | $17,503 | $273 |
| Anastrozole | 484 | $13,706 | $28 |
| Dronabinol | 13 | $9,382 | $722 |
| Letrozole | 143 | $6,662 | $47 |
| Hydrocodone-Acetaminophen | 118 | $4,207 | $36 |
| Cymbalta | 18 | $3,549 | $197 |
| Hydroxyurea | 84 | $2,885 | $34 |
| Morphine Sulfate Er | 18 | $2,039 | $113 |
| Hydromorphone | 16 | $1,536 | $96 |
| Ondansetron | 58 | $1,038 | $18 |
| Tamoxifen Citrate | 38 | $644 | $17 |
| Lorazepam | 111 | $617 | $6 |
| Gabapentin | 32 | $428 | $13 |
| Megestrol Acetate | 11 | $417 | $38 |
| Prochlorperazine Maleate | 32 | $233 | $7 |
| Warfarin | 11 | $171 | $16 |
| Trazodone | 21 | $77 | $4 |
| Zolpidem | 14 | $63 | $5 |
| Prednisone | 11 | $53 | $5 |
| Dexamethasone | 11 | $47 | $4 |
Money from drug and device companies
$1,374 in 2025
| 2025 | 25 | 54 | None | $1,374 |
| 2024 | 17 | 35 | None | $931 |
| 2023 | 21 | 46 | None | $1,294 |
| 2022 | 26 | 52 | None | $1,315 |
| 2021 | 17 | 27 | None | $555 |
| 2020 | 8 | 13 | None | $278 |
| 2019 | 28 | 123 | None | $1,713 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Libtayo | $167 | 5 payments
|
| Genentech USA | Itovebi | $150 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $113 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $111 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $84 | 3 payments
|
| Caris MPI | Mi Cancer Seek | $57 | 2 payments
|
See all 54 published payments
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-18 | Nubeqa | $23 |
| Genzyme | Meals · 2025-12-17 | Ayvakit | $35 |
| GlaxoSmithKline | Meals · 2025-12-10 | Jemperli | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-12-09 | Libtayo | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-04 | Opdivo | $28 |
| Pfizer | Meals · 2025-11-25 | Xtandi | $30 |
| Immunocore | Meals · 2025-11-13 | Kimmtrak | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-11 | Lynparza | $28 |
| Caris MPI | Meals · 2025-11-06 | Mi Cancer Seek | $30 |
| Janssen Biotech | Meals · 2025-10-30 | Rybrevant | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-10-23 | Libtayo | $35 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Kisqali | $30 |
| Array Biopharma | Meals · 2025-10-15 | Braftovi | $26 |
| Verity Pharmaceuticals | Meals · 2025-10-10 | Trelstar | $20 |
| Genentech USA | Meals · 2025-10-09 | Phesgo | $20 |
| Genentech USA | Meals · 2025-10-09 | Phesgo | $1 |
| Genentech USA | Meals · 2025-10-09 | Phesgo | $2 |
| Incyte | Meals · 2025-10-08 | Monjuvi | $26 |
| Eisai | Meals · 2025-10-07 | Lenvima | $26 |
| Tempus AI | Meals · 2025-09-11 | Xt Cdx | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-10 | Advate | $35 |
| Immunocore | Meals · 2025-09-04 | Kimmtrak | $25 |
| Daiichi Sankyo | Meals · 2025-08-28 | Datroway | $27 |
| Regeneron Healthcare Solutions | Meals · 2025-08-26 | Libtayo | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-14 | Lynparza | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-31 | Opdualag | $27 |
| Merck Sharp & Dohme | Meals · 2025-07-24 | Keytruda | $26 |
| Incyte | Meals · 2025-07-10 | Monjuvi | $25 |
| Exelixis | Meals · 2025-07-04 | Cabometyx | $35 |
| Genentech USA | Meals · 2025-07-03 | Itovebi | $8 |
| Abbvie | Meals · 2025-07-01 | Venclexta | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-26 | None | $28 |
| Array Biopharma | Meals · 2025-06-23 | Braftovi | $21 |
| Eisai | Meals · 2025-06-19 | Lenvima | $21 |
| Genentech USA | Meals · 2025-06-12 | Itovebi | $20 |
| Regeneron Healthcare Solutions | Meals · 2025-06-06 | Libtayo | $38 |
| Merck Sharp & Dohme | Meals · 2025-05-15 | Keytruda | $29 |
| Caris MPI | Meals · 2025-05-08 | Mi Cancer Seek | $28 |
| Genentech USA | Meals · 2025-05-01 | Itovebi | $19 |
| Daiichi Sankyo | Meals · 2025-04-30 | Enhertu | $15 |
| Regeneron Healthcare Solutions | Meals · 2025-04-25 | Libtayo | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-24 | Opdivo | $29 |
| Pfizer | Meals · 2025-04-15 | Elrexfio | $25 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Kisqali | $22 |
| Deciphera Pharmaceuticals | Meals · 2025-03-06 | Qinlock | $43 |
| Merck Sharp & Dohme | Meals · 2025-02-28 | Keytruda | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-27 | Opdualag | $30 |
| Progenics Pharmaceuticals | Meals · 2025-02-26 | Pylarify | $19 |
| Genentech USA | Meals · 2025-02-13 | Tecentriq | $24 |
| Genentech USA | Meals · 2025-02-13 | Tecentriq | $0 |
| Astellas Pharma US | Meals · 2025-01-31 | Xtandi | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-30 | Enhertu | $23 |
| Genentech USA | Meals · 2025-01-23 | Venclexta | $26 |
| Genentech USA | Meals · 2025-01-16 | Itovebi | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $931
| Astellas Pharma US | Vyloy | $149 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $135 | 7 payments
|
| Novartis Pharmaceuticals | Lutathera | $109 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $104 | 4 payments
|
| Genentech USA | Polivy | $85 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $56 | 2 payments
|
| Eisai | Lenvima | $47 | 2 payments
|
| Deciphera Pharmaceuticals | Qinlock | $34 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $31 | 1 payment
|
| Taiho Oncology | Lonsurf | $31 | 1 payment
|
| Janssen Biotech | Rybrevant | $27 | 1 payment
|
| Abbvie | Venclexta | $26 | 1 payment
|
| Coherus Biosciences | Udenyca | $25 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $21 | 1 payment
|
| Ipsen Biopharmaceuticals | Onivyde | $18 | 1 payment
|
| Azurity Pharmaceuticals | Vivimusta | $16 | 1 payment
|
| BeiGene USA | Brukinsa | $15 | 1 payment
|
2023: $1,294
| Novartis Pharmaceuticals | Kisqali | $398 | 7 payments
|
| Genentech USA | Tecentriq | $186 | 10 payments
|
| Merck Sharp & Dohme | Keytruda | $83 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $77 | 3 payments
|
| GlaxoSmithKline | Zejula | $71 | 3 payments
|
| Jazz Pharmaceuticals | Zepzelca | $66 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $61 | 2 payments
|
| Organon | Ontruzant | $43 | 2 payments
|
| Astellas Pharma US | Padcev | $31 | 2 payments
|
| Pharmacosmos Therapeutics | Monoferric | $30 | 1 payment
|
| AbbVie | Venclexta | $28 | 1 payment
|
| Janssen Biotech | Rybrevant | $27 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $25 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $24 | 1 payment
|
| Pfizer | Ibrance | $23 | 1 payment
|
| Kite Pharma | None | $23 | 1 payment
|
| Incyte | Pemazyre | $21 | 1 payment
|
| Daiichi Sankyo | Enhertu | $19 | 1 payment
|
| Seagen | Tivdak | $19 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $15 | 1 payment
|
2022: $1,315
| Novartis Pharmaceuticals | Kisqali | $245 | 4 payments
|
| Genentech USA | Venclexta | $149 | 9 payments
|
| Incyte | Jakafi | $113 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $88 | 3 payments
|
| Amgen | Nplate | $68 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $58 | 2 payments
|
| Pfizer | Ibrance | $58 | 3 payments
|
| Regeneron Healthcare Solutions | Libtayo | $55 | 2 payments
|
| Abbvie | Lupron Depot | $50 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $41 | 2 payments
|
| Eisai | Lenvima | $39 | 2 payments
|
| Daiichi Sankyo | Injectafer | $34 | 2 payments
|
| Lilly USA | Cyramza | $34 | 1 payment
|
| GE HealthCare | None | $28 | 1 payment
|
| Kite Pharma | None | $26 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Akynzeo | $24 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $24 | 1 payment
|
| ADC Therapeutics America | None | $24 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $23 | 1 payment
|
| Myovant Sciences | Orgovyx | $23 | 1 payment
|
| EMD Serono | None | $22 | 1 payment
|
| Exelixis | Cabometyx | $22 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $20 | 1 payment
|
| Genzyme | Sarclisa | $16 | 1 payment
|
| Astellas Pharma US | Padcev | $16 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $15 | 1 payment
|
2021: $555
| Myovant Sciences | Orgovyx | $67 | 3 payments
|
| Genzyme | Libtayo | $65 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $46 | 2 payments
|
| Genentech USA | Phesgo | $46 | 2 payments
|
| Pfizer | Ibrance | $45 | 2 payments
|
| Daiichi Sankyo | Enhertu | $40 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $39 | 2 payments
|
| Janssen Biotech | Erleada | $33 | 2 payments
|
| Amgen | Nplate | $26 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $24 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $23 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $20 | 1 payment
|
| Novartis Pharmaceuticals | Tasigna | $18 | 1 payment
|
| Astellas Pharma US | Padcev | $15 | 1 payment
|
| AbbVie | Venclexta | $12 | 1 payment
|
| GlaxoSmithKline | Zejula | $12 | 1 payment
|
2020: $278
| Merck Sharp & Dohme | Keytruda | $61 | 3 payments
|
| Amgen | Prolia | $51 | 2 payments
|
| Seagen | Tukysa | $48 | 2 payments
|
| Genentech USA | Perjeta | $47 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $21 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $19 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $17 | 1 payment
|
| Astellas Pharma US | Padcev | $15 | 1 payment
|
2019: $1,713
| Pfizer | Ibrance | $194 | 18 payments
|
| Genentech USA | Perjeta | $181 | 18 payments
|
| Amgen | Nplate | $145 | 10 payments
|
| Astellas Pharma US | Xtandi | $129 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $117 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $111 | 5 payments
|
| Janssen Biotech | Erleada | $106 | 11 payments
|
| Novartis Pharmaceuticals | Mekinist | $87 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $82 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $73 | 4 payments
|
| Clovis Oncology | Rubraca | $70 | 3 payments
|
| AbbVie | Venclexta | $47 | 2 payments
|
| Seattle Genetics | Adcetris | $44 | 2 payments
|
| Eisai | Lenvima | $40 | 2 payments
|
| Lilly USA | Verzenio | $37 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $37 | 2 payments
|
| Kyowa Kirin | Poteligeo | $30 | 2 payments
|
| Celgene | Pomalyst | $26 | 2 payments
|
| Tesaro | Zejula | $21 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $19 | 1 payment
|
| Shire North American Group | None | $19 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $17 | 1 payment
|
| Gilead Sciences | None | $17 | 1 payment
|
| Genzyme | Jevtana | $16 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $14 | 1 payment
|
| Taiho Oncology | Lonsurf | $13 | 1 payment
|
| Verastem | Copiktra | $12 | 1 payment
|
| Janssen Pharmaceuticals | Darzalex | $8 | 1 payment
|
Professional record
- NPI
- 1598731291
- Licence
- CA G065481California G65481: Current · expires 2027-02-28
- Trained
- St. Louis College of Physicians and Surgeons, 1983 · 43 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 6555 Coyle Ave, Ste 301, Carmichael, CA, 95608
- NPI first listed
- 2006-02-23
- NPI last updated
- 2017-04-28
This is when the NPI record was last certified, not a medical board exam.